The AUC for pancreatic cancer diagnosis by serum EphA2-NF (vs. test cohort HDs) in the CA19-9–low (<37.0 U/mL) group was 0.89, suggesting that serum EphA2-NF has excellent diagnostic ability regardless of the CA19-9 level. Here, EPHA2 is linked to pancreatic neoplasm.